Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators
Open Access
- 1 November 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 46 (5) , 1086-1092
- https://doi.org/10.1161/01.hyp.0000187900.36455.4c
Abstract
Fibric acid is a synthetic ligand of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-α that is highly expressed in skeletal muscle and heart, where it promotes β-oxidation of fatty acids to mediate hypolipidemic actions. PPAR-α regulates expression of key proteins involved in atherogenesis, vascular inflammation, plaque instability, and thrombosis. Thus, PPAR-α may exert direct antiatherogenic actions in the vascular wall. Endothelial dysfunction associated with the metabolic syndrome and other insulin-resistant states is characterized by impaired insulin-stimulated nitric oxide production from the endothelium and decreased blood flow to skeletal muscle. Thus, improvement in insulin sensitivity leads to improved endothelial function. This may be an additional mechanism whereby fibrates decrease the incidence of coronary heart disease. Adiponectin is a protein secreted specifically by adipose cells that may couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance. In this review, we discuss the mechanisms underlying the vascular and metabolic effects of fibrates that may act synergistically to prevent or regress atherosclerosis and coronary heart disease.Keywords
This publication has 54 references indexed in Scilit:
- The benefit of fibrates in the treatment of ‘bad HDL-C responders to statins’International Journal of Cardiology, 2005
- Fenofibrate Prevents the Development of Angiotensin II–Dependent Hypertension in MiceHypertension, 2005
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)The American Journal of Cardiology, 2005
- Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinThe American Journal of Cardiology, 2005
- Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXRBiochemical and Biophysical Research Communications, 2003
- PPARα Activator Effects on Ang II–Induced Vascular Oxidative Stress and InflammationHypertension, 2002
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery diseaseCoronary Artery Disease, 1996
- Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1986